Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis and Alnylam ally on RNAi drugs
September 12, 2005
| A version of this story appeared in
Volume 83, Issue 37
Novartis and Alnylam are beginning a three-year alliance to apply the gene-silencing technology RNA interference (RNAi) in drug discovery. Novartis will pay Alnylam $56.8 million, consisting of cash and the purchase of 19.9% of the firm's stock. If Novartis integrates Alnylam's technology into its drug discovery platform, Alnylam will be eligible for royalties on products resulting from those efforts. Alnylam will continue developing its own pipeline of RNAi therapeutics while giving Novartis the right of first offer for those drug candidates.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter